Skip to content

Medical emergency? What to do

Evidence Supports First Non-Injectable Insulin as Alternative Treatment for Diabetes

3-RXPublished November 22, 20053 min read

Key points

  • There is clear evidence from clinical trials that a new inhaled formulation of insulin, Exubera®, is as effective as traditional subcutaneous injections in controlling blood glucose in patients with type 1 or type 2 diabetes.
  • Diabetes affects an estimated 194 million people worldwide, and prevalence is expected to almost double within the next 20 years.
  • “One reason for this is that physicians and patients are often reluctant to initiate insulin therapy, because of the burden of daily injections, and the risk of hypoglycemia and weight gain,” said Louise Profit, PhD, author of the review.
  • The review in Core Evidence states that there is clear evidence that Exubera is as effective as subcutaneous insulin in reducing HbA1c levels, the key indicator of blood glucose control, in patients with type 1 or type 2 diabetes.

There is clear evidence from clinical trials that a new inhaled formulation of insulin, Exubera®, is as effective as traditional subcutaneous injections in controlling blood glucose in patients with type 1 or type 2 diabetes. The new formulation, which is likely to be the first non-injectable insulin on the market, was preferred by a majority of patients due to ease of use.

Clinical trials with Exubera are reviewed in the journal Core Evidence, the first international peer-reviewed publication to assess medications by critically evaluating evidence on clinical effectiveness and outcomes.

Diabetes affects an estimated 194 million people worldwide, and prevalence is expected to almost double within the next 20 years. Type 2 diabetes is the most common form of the disease, accounting for over 90% of cases. In most patients, the disease is initially controlled by diet and exercise, usually with the addition of oral antidiabetic medications. However, many patients will require insulin therapy over the course of their disease to control blood glucose and avoid serious complications including cardiovascular disease, neuropathy, and nephropathy. Insulin is the mainstay of treatment of type 1 diabetes.

However, despite the well known benefit of tight management of blood glucose, it is estimated that many patients are not adequately controlled, particularly those with type 2 diabetes.

“One reason for this is that physicians and patients are often reluctant to initiate insulin therapy, because of the burden of daily injections, and the risk of hypoglycemia and weight gain,” said Louise Profit, PhD, author of the review. “Alternative routes of insulin administration are therefore being investigated.”

Exubera is a dry powder formulation packaged into blisters and delivered via a hand-held inhaler device developed by Nektar Therapeutics. It is jointly developed by Pfizer and Sanofi-Aventis, and is likely to be the first available non-injectable insulin on the market. Its approval has been recommended by an FDA Advisory Board in the United States, and by the Committee for Medicinal Products for Human Use of the European Medicines Agency.

The review in Core Evidence states that there is clear evidence that Exubera is as effective as subcutaneous insulin in reducing HbA1c levels, the key indicator of blood glucose control, in patients with type 1 or type 2 diabetes. The article also found that “inhaled insulin had a greater acceptance relating to convenience and ease of use.” The incidence of weight gain and hypoglycemia was no greater with Exubera compared with subcutaneous insulin, and in short-term trials there was no effect on pulmonary function.

Although no economic analyses have been published, the review suggests that Exubera may prove cost effective if it improves blood glucose control through better patient acceptability. “Even a 1% increase in HbA1c can increase healthcare costs because of more frequent and earlier onset of diabetic complications,” said Dr Profit. “Drugs make up a relatively small proportion of the overall cost of managing diabetes, which may be offset by savings from better disease control. However, comparisons with other inhaled insulin formulations and formal economic studies are required to confirm this for Exubera.”

The article nevertheless concludes that “current evidence suggests that Exubera is an alternative to short-acting subcutaneous insulin therapy providing a further choice for the treatment of patients with type 1 or type 2 diabetes,” and that “a major benefit of Exubera…appears to be the improvement in patient treatment satisfaction which is related to its ease of use, leading to better adherence to treatment.”

The content on this site is for information only and is not a substitute for professional medical advice, diagnosis or treatment. Drug information pages are an archive and may be out of date: always follow your prescriber, your pharmacist and the current product label. In an emergency, call 911.

Filed underDiabetes

Keep reading

When to get help

Reading is for later. These need care now.

Call 911 or go to an emergency department if you or someone with you has any of these:

  • Chest pain or pressureEspecially with breathlessness, sweating or pain in the arm, jaw or back. It can be a heart attack.
  • Face drooping, arm weakness, slurred speechSigns of a stroke. Note the time they started: treatment works best within hours.
  • Severe trouble breathingIncluding a severe allergic reaction with swelling of the lips, tongue or throat.
  • Thoughts of suicideCall or text 988 (Suicide & Crisis Lifeline, US) any time, day or night.

Outside the US, call your local emergency number.

See a doctor within days

  1. 01A new lump, or a sore that does not healMost lumps are harmless, but anything that grows or lasts more than a few weeks should be checked.
  2. 02Unexplained weight loss or lasting fatigueLosing weight without trying, or tiredness that does not lift, can have many causes worth finding.
  3. 03A new medicine and new symptomsSide effects and interactions are common. Ask your pharmacist or prescriber before you stop anything.

General guidance only. If you are unsure how urgent a symptom is, call your doctor or a nurse advice line.